Herantis Pharma: Announces positive phase Ia data - Redeye

Redeye endorses today’s news that Herantis has presented positive phase Ia data with HER-096, and the company states that “The clinical trial demonstrated favorable safety and tolerability, fast uptake of HER-096, and significant HER-096 concentrations in the cerebrospinal fluid (CSF) after a single subcutaneous injection.” We will participate during the webinar that will start shortly and then return with an additional take, where we expect to raise our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/950135/herantis-pharma-announces-positive-phase-ia-data?utm_source=finwire&utm_medium=RSS